2-(2-dimethylamino-ethyl)-5-isothiocyanato-isoindole-1,3-dione | 486415-51-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-(2-dimethylamino-ethyl)-5-isothiocyanato-isoindole-1,3-dione
• 英文别名: 2-[2-(Dimethylamino)ethyl]-5-isothiocyanatoisoindole-1,3-dione
• CAS: 486415-51-4
• 化学式: C₁₃H₁₃N₃O₂S
• 分子量: 275.331
• InChiKey: ZGHTUNRCGAHDNH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  85.1
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use
  申请人：——

  公开号：US20030225147A1

  公开（公告）日：2003-12-04

  Aminothiazole compounds with mono-/di-substituted benzamide are represented by the Formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, pharmaceutically active metabolites, and pharmaceutically acceptable salts of said metabolites are described. 1 These agents modulate and/or inhibit the cell proliferation and activity of protein kinases and are useful as pharmaceuticals for treating malignancies and other disorders.

  氨基噻唑化合物与单取代/双取代苯甲酰胺的结构由式(I)表示，并描述了它们的药学上可接受的盐、药学上可接受的前药、药学上活性代谢物以及所述代谢物的药学上可接受的盐。 这些药物调节和/或抑制细胞增殖和蛋白激酶活性，并可用作治疗恶性肿瘤和其他疾病的药物。
• THIAZOLE BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION, AND METHODS FOR THEIR USE
  申请人：AGOURON PHARMACEUTICALS, INC.

  公开号：EP1438046A2

  公开（公告）日：2004-07-21
• EP1438046A4
  申请人：——

  公开号：EP1438046A4

  公开（公告）日：2004-10-20
• US6720346B2
  申请人：——

  公开号：US6720346B2

  公开（公告）日：2004-04-13
• [EN] THIAZOLE BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION, AND METHODS FOR THEIR USE<br/>[FR] DERIVES DE BENZAMIDE DE THIAZOLE ET COMPOSITIONS PHARMACEUTIQUES INHIBANT LA PROLIFERATION CELLULAIRE, ET METHODES D'UTILISATION
  申请人：AGOURON PHARMA

  公开号：WO2003004467A2

  公开（公告）日：2003-01-16

  Aminothiazole compounds with mono-/di-substituted benzamide are represented by the Formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, pharmaceutically active metabolites, and pharmaceutically acceptable salts of said metabolites are described. These agents modulate and/or inhibit the cell proliferation and activity of protein kinases and are useful as pharmaceuticals for treating malignancies and other disorders.